NUVARA THERAPEUTICS - Key Persons
Job Titles:
- Senior Advisor / Chief of Pediatric Pulmonary at Mass General Director of Pulmonary Genetics and Pulmonary Functions at Mass General
Brian Fox, CEO of Junonia Capital, has an established track record of creating and building health care companies through industry expertise and access to capital. He is a founder and Executive Chairman of Millennium Healthcare, the largest independent primary care practice in Florida. In 2014, through a founding investment, Mr. Fox helped create Community Based Care Integrated Health, a care coordination service provider.
Job Titles:
- General Counsel / Senior Partner in the Boston Corporate Practice at McDermott
Job Titles:
- Senior Vice President, Business Development
Dennis Crowley is senior vice president, Business Development & Licensing. Crowley joined Baxter in 2017 from Acelity L.P., where he served as senior vice president, Strategy and Business Development. Previously, he worked at Medtronic plc (and before that, Covidien plc) in roles of increasing responsibility between 2005 and 2015, most recently as vice president, Corporate Development. Crowley began his professional career with Tyco Healthcare in 1993 and served in various strategic, business development and operational roles during his 12-year tenure. Crowley received his bachelor's degree in economics from Harvard College.
Job Titles:
- Member of the Board of Directors
- Managing Director and Chief Investment Officer With the Autism Impact Fund
Dr. Charlotte Hubbert is Managing Director and Chief Investment Officer with the Autism Impact Fund where she leads the Life Sciences practice. Charlotte was previously Partner and head of Gates Foundation Venture Capital, a $500mm initiative at the Bill and Melinda Gates Foundation Strategic Investment Fund where she oversaw investing in innovative technologies that supported the foundation's programs in global health and agriculture. Notably she led investments and served on the board of directors of Synlogic (Nasdaq: SYBX), Sera Prognostics, Lodo Therapeutics, Agtech Accelerator, Vedanta, and Vir Biotechnology (Nasdaq: VIR). Charlotte currently serves on the BODs of Entrinsic Health and Galileo Biosystems. Prior to joining the foundation, Charlotte was a vice president at H.I.G. BioVentures, investing broadly in healthcare. Charlotte began her career in early-stage biotech, investing at Accelerator Corporation, where she was part of the founding team and oversaw management of five companies: Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori, and Pharmselex. Charlotte earned a B.S. in microbiology from the University of Washington and a Ph.D. in pharmacology and cancer biology from Duke University for which she received the prestigious Harold Weintraub Award. She did her post-doctoral work in stem cells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the UW. Charlotte is a member of the Kauffman Society of Fellows (Class 14) and serves on the BOD of Life Science Washington, and the steering committees of the Fred Hutch Cancer Institute's Evergreen Fund, UW Innovation Roundtable and Columbia University Lab-to-Market initiative. Charlotte has been honored as a Fierce Woman in Biopharma 2016 by FiercePharma, and as a leading Woman in Life Sciences 2016 by Life Science Washing
• The Bridges' Laboratory works with biotech companies discovering new Cystic Fibrosis therapeutics
Job Titles:
- Chairman of the Scientific Advisory Board, Yale School of Medicine
Job Titles:
- President and CEO of the Massachusetts Biotechnology Council
As President and CEO of the Massachusetts Biotechnology Council, Bob's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives. Over the last decade, Bob has truly become a champion for patients by ensuring innovative companies have the best environment possible to research, develop, and commercialize breakthrough therapies and cures for people around the world who need and deserve them. Bob has spent his career in both the public and private sectors. Before joining MassBio, he served as the Undersecretary of Economic Development within Governor Deval Patrick's administration, where he prioritized both healthcare and economic development issues and was a strong advocate for the life sciences industry in Massachusetts. Prior to that, he was elected as State Representative to the 11th Norfolk district for three terms. Bob has also held senior executive positions in the environmental services, capital management and venture capital industries.
Robin Walker is a Strategic Executive with over twenty years of experience navigating compliance, corporate governance, regulatory, risk management, M&A, IP, and legal expertise for publicly traded and privately held biotechnology pharmaceutical and retail companies, including Goldfinch Bio, Biogen (Nasdaq: BIIB), Stoke Therapeutics, Inc. (Nasdaq: STOK), and Staples. Walker brings to public and high-growth company boards a valuable understanding of navigating from R&D through commercialization of wide-ranging, ultra-rare to large patient population diseases, creating post-IPO growth strategies while ensuring compliance and mitigating risk.
Job Titles:
- Member of the Board of Directors
- Executive Chairman / Myriant Corporation
Prior Chairman and Chief Executive Officer of Myriant Corporation and Chief Executive Officer of BC International Corp., Mr. Gatto has served on numerous presidential, congressional and US DOE/DOA committees and was appointed by the Clinton and Bush administrations, respectively, to the Biomass Research & Development Technical Advisory Committee.
Job Titles:
- Chief Medical Advisor / Chief Medical Officer and Co - Founder of Scilogica